Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Biotechnology Pharmaceutical Company Selects NewCardio's QTinno for Thorough QT Trial Fully Automated ECG Analysis, Empowered by QTinno, to be Delivered through Integrated Clinical Trial Services...
NewCardio Announces Changes in Board of Directors and Executive Management PR Newswire PRINCETON, N.J., Jan. 10, 2012 PRINCETON, N.J., Jan. 10, 2012 /PRNewswire/ -- NewCardio, Inc., (OTC BB:...
Top 3 Clinical Research Organization Selects QTinno for a Phase I Drug Safety Trial Fully Automated ECG Analysis, Empowered by QTinno, will be used to confirm previous cardiac safety analysis PR...
NewCardio Announces Financial Results for its 2011 Third Quarter PR Newswire PRINCETON, N.J., Nov. 15, 2011 PRINCETON, N.J., Nov. 15, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC BB: NWCI) a...
Clinilabs will Conduct Phase 1 Trial Using QTinno® NewCardio Schedules Conference Call for November 15, 2011 to Update Shareholders PR Newswire SANTA CLARA, Calif., Nov. 9, 2011 SANTA CLARA...
Top 5 Global Pharmaceutical Company Selects NewCardio's QTinno for Phase I Drug Safety Trial Fully Automated ECG Analysis, Empowered by QTinno, to be Delivered Through Integrated Clinical Trial...
NewCardio Announces Financial Results for Its 2011 Second Quarter PR Newswire SANTA CLARA, Calif., Aug. 15, 2011 SANTA CLARA, Calif., Aug. 15, 2011 /PRNewswire/ -- NewCardio, Inc., (OTC BB: NWCI...
NewCardio to Present at Wells Fargo Securities Healthcare Conference Presentation Scheduled for 3:30 p.m. ET on June 22, 2011 PR Newswire SANTA CLARA, Calif., June 17, 2011 SANTA CLARA, Calif...
NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society Data Validate Effectiveness of both NewCardio Products CardioBip™ and...
NewCardio to Showcase Cardiac Diagnostic Technology at MDB Capital's Bright Lights Conference in New York City on May 10, 2011 NewCardio Among MDB Capital Group's Small-Cap IP Leaders PR...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 150000 | 1.0E-6 | CS |
| 4 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 94790 | 1.0E-6 | CS |
| 12 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 94790 | 1.0E-6 | CS |
| 26 | 0 | 0 | 1.0E-6 | 1.0E-6 | 1.0E-6 | 37976 | 1.0E-6 | CS |
| 52 | -9.0E-6 | -90 | 1.0E-5 | 1.0E-5 | 1.0E-6 | 17425 | 1.03E-6 | CS |
| 156 | -9.9E-5 | -99 | 0.0001 | 0.00066 | 1.0E-6 | 9406 | 2.148E-5 | CS |
| 260 | -0.002799 | -99.9642857143 | 0.0028 | 0.005 | 1.0E-6 | 97063 | 0.00141346 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
